(Q33767470)

29 July 2017

title

Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv (English)

1 reference

29 July 2017

1 reference

8

Robert Blumenthal

1 reference

29 July 2017

4

Himanshu Garg

1 reference

29 July 2017

Kristin Loomis

1

1 reference

29 July 2017

Brandon Smith

2

1 reference

29 July 2017

Yang Feng

3

1 reference

29 July 2017

Amichai Yavlovich

5

1 reference

29 July 2017

Ryan Campbell-Massa

6

1 reference

29 July 2017

Dimiter S Dimitrov

7

1 reference

29 July 2017

Xiaodong Xiao

9

1 reference

29 July 2017

Anu Puri

10

1 reference

29 July 2017

publication date

1 February 2010

1 reference

Experimental and Molecular Pathology

29 July 2017

published in

1 reference

29 July 2017

volume

88

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

238-249

1 reference

The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Targeted pharmaceutical nanocarriers for cancer therapy and imaging

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Future directions of liposome- and immunoliposome-based cancer therapeutics

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Cytotoxic tumor targeting with scFv antibody-modified liposomes.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Epratuzumab in non-Hodgkin's lymphomas

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Epratuzumab: targeting B-cell malignancies through CD22

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

CD22-directed monoclonal antibody therapy for lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Ligand-targeted liposomal anticancer drugs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Ligand-targeted therapeutics in anticancer therapy

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Design and synthesis of a multivalent homing device for targeting to murine CD22.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Carbamyl analogs of phosphatidylcholines. Synthesis, interaction with phospholipases and permeability behavior of their liposomes.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Design of Liposomes for Enhanced Local Release of Drugs by Hyperthermia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Surface modification of liposomes by saccharides: vesicle size and stability of lactosyl liposomes studied by photon correlation spectroscopy

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2849008

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma

30 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.006

Trends and developments in liposome drug delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.006

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.006

HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.006

Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.006

The role of multivalency in antibody mediated liposome targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXMP.2010.01.006

Spray detection of phospholipids on thin-layer chromatograms

7 January 2021

1 reference

12 December 2020

The monoclonal antibodies alpha S-HCL 1 (alpha Leu-14) and alpha S-HCL 3 (alpha Leu-M5) allow the diagnosis of hairy cell leukemia

1 reference

12 December 2020

HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes

1 reference

12 December 2020

Constitutive endocytosis and degradation of CD22 by human B cells

1 reference

12 December 2020

The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid

1 reference

12 December 2020

The Role of Polyamines in the Neutralization of Bacteriophage Deoxyribonucleic Acid

1 reference

19 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/S0021-9258(19)67936-6

Identifiers

DOI

10.1016/J.YEXMP.2010.01.006

1 reference

29 July 2017

1 reference

29 July 2017

1 reference